Ribavirin Injection
Function and Efficacy
1. Pharmacology: Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro, and its mechanism is not fully understood. This product does not change the adsorption, invasion and uncoating of viruses, nor does it induce the production of interferon. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, damaging viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. 2. Toxicology: Animal experiments have found that this product can induce benign tumors of the breast, pancreas, pituitary and adrenal glands, but its carcinogenicity to humans has not been confirmed. The drug can cause malformations of the head, palate, eyes, jaw, bones and gastrointestinal tract in animals such as hamsters, and reduce the survival of offspring, but primate experiments have not found any effect of the drug on the fetus. Cardiac damage occurred in mice, rats, and monkeys given oral ribavirin at doses of 30, 36, and 120 mg/kg or more for 4 weeks (equivalent to human doses: 4.8, 12.3, and 111.4 mg/kg for a 5 kg child, or 2.5, 5.1, and 40 mg/kg for a 60 kg adult).
Ingredients
The main ingredient of this product is: Ribavirin.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| RibavirinIngredients |
Broad-spectrum antiviral drug. It has the effect of inhibiting the growth of multiple viruses such as respiratory syncytial virus, influenza virus, hepatitis A virus, adenovirus, etc. in vitro. After entering the virus-infected cells, the drug is rapidly phosphorylated, and its product acts as a competitive inhibitor of viral synthase, inhibiting inosine monophosphate dehydrogenase, influenza virus RNA polymerase and mRNA guanosine transferase, thereby causing a decrease in intracellular guanosine triphosphate, impairing viral RNA and protein synthesis, and inhibiting viral replication and transmission. It may also have an immune effect and neutralizing antibody effect on respiratory syncytial virus. More |
36791-04-5 | 33 |
Appearance
This product is a colorless clear liquid.
Indication
Antiviral drug. Used for viral pneumonia and bronchitis caused by respiratory syncytial virus.
Usage and Dosage
Dilute with sodium chloride injection or 5% glucose injection to a solution containing 1 mg per 1 ml and then slowly drip intravenously. Adults take 0.5 g at a time, twice a day, and children take 10-15 mg/kg per day according to body weight, divided into 2 doses. Each drip should last for more than 20 minutes, and the course of treatment is 3-7 days.
Adverse Reactions
Common adverse reactions include anemia and fatigue, which disappear after stopping the drug. Less common adverse reactions include fatigue, headache, insomnia, loss of appetite, nausea, vomiting, etc., and can cause a decrease in red blood cells, white blood cells and hemoglobin.
Precautions
It is forbidden for people who are allergic to this product and pregnant women.
Special Population Medication
Precautions during pregnancy and lactation: Contraindicated for use during pregnancy.
Drug Interactions
This product has an antagonistic effect when used together with zidovudine, because this product can inhibit the conversion of zidovudine into active zidovudine phosphate.
Storage
Keep tightly closed.
Packaging Specification
1ml:100mg
Manufacturer
Shanxi JINXIN DOUBLE-CRANE Pharmaceutical Co., Ltd.
-
Founded in:
2001-12-14 -
Address:
Sanlidun, North of Xia County, Yuncheng City, Shanxi Province -
Tax NO.:
911408287281430205 -
Registered Funds:
164.191 million yuan -
Website:
-
Email: